Boston QSP is excited to announce our November event in the Modeling & Simulation in Drug Development series. This event will feature a talk by Dr. Alison Betts, Sr. Director of Scientific Collaborations and Fellow of Modeling & Simulation. The talk is titled "Translational modeling strategies to predict clinical starting and efficacious doses for CD3-bispecific molecules" and will be followed by a mixer and reception where you can enjoy great company and conversation with fellow community members over chilled craft beers and delicious pizza from a local small business.
The venue is sponsored by CIC. The event sponsor is Amgen.
5:00-5:30 PM: Registration (outside Havana Room)
5:30-6:20 PM: Presentation and Q&A. Presentation title: “Translational modeling strategies to predict clinical starting and efficacious doses for CD3-biospecific molecules” (Havana Room)
6:20-7:30 PM: Mixer & Reception (Venture Café, a few steps down the hallway from the
Venue: Cambridge Innovation Center, 1 Broadway, Cambridge.
RSVP here Limited seats. * Please do not hesitate to RSVP on the waiting list if the RSVP is full as some guests "un-RSVP" as the event gets closer.
Dr. Alison Betts recently joined Applied Biomath as Sr. Director of Scientific Collaborations and Fellow of Modeling & Simulation. Here she is part of the Business Development team providing scientific support and partner alignment based on her vast modeling experience in industry. Prior to joining Applied Biomath, Alison had an extensive modeling career at Pfizer, across many therapeutic domains. Most recently, she was modeling and simulation (M&S) lead supporting the Oncology Research Unit. In this role she led a team responsible for using M&S strategies to answer mechanistic questions, validate targets, select optimal compounds and translate to the clinic. Alison specializes in M&S of novel biotherapeutic modalities including bi-specific T-cell retargeting molecules, CAR-T cells, targeted nanoparticles and drug conjugates for treatment of cancer.
A translational quantitative systems pharmacology (QSP) model is proposed for CD3 bispecific molecules capable of predicting trimolecular complex (trimer) concentration between drug, T-cell and tumor cell, and linking it to tumor cell killing. The model was used to 1) predict clinical starting dose of a P-cadherin/ CD3 bispecific construct (Pcad-LP-DART) using a MABEL approach 2) to characterize the in vivo PK/PD relationship of Pcad-LP-DART across mouse xenograft efficacy models 3) to translate from mouse to human for Pcad-LP-DART for prediction of clinical efficacy and for sensitivity analysis to determine important parameters driving efficacy. The model can also be applied at early stages to aid in the design of CD3 bispecific constructs and to select molecules with optimal properties.
Event Sponsored by:
Venue Sponsored by:
About Boston QSP
Boston QSP is a 501(c)(3) non-profit organization whose mission is to foster the sharing of QSP knowledge, challenges, solutions, and opportunities to advance the field as an interdisciplinary community in Boston.